Vaxcyte, Inc. - Understand $pcvx stock

$PCVX Market Cap: $11.6 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$507.6M

TTM

Current Assets

$2.214B

Q3 2024

Current Liabilities

$123.8M

Q3 2024

Current Ratio

1788.4%

Q3 2024

Total Assets

$3.560B

Q3 2024

Total Liabilities

$142.1M

Q3 2024

Book Value

$3.418B

Q3 2024

Cash

$1.050B

Q3 2024

P/E

-22.84

Nov 29, 2024 EST

Free Cash Flow

-$609.8M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017
Selling, General & Admin	$125.0M	$73.59M	$42.74M	$16.02M	$8.550M	$5.390M	$5.050M
YoY Change	69.83%	72.19%	166.76%	87.37%	58.63%	6.73%
% of Gross Profit
Research & Development	$332.3M	$169.5M	$78.41M	$73.56M	$45.61M	$30.15M	$12.79M
YoY Change	96.13%	116.11%	6.59%	61.3%	51.29%	135.69%
% of Gross Profit
Depreciation & Amortization	$3.156M	$2.577M	$1.800M	$1.405M	$1.232M	$1.040M	$630.0K
YoY Change	22.47%	43.17%	28.11%	14.04%	18.46%	65.08%
% of Gross Profit
Operating Expenses	$468.0M	$232.3M	$103.7M	$89.58M	$54.15M	$35.53M	$17.83M
YoY Change	101.52%	124.03%	15.73%	65.42%	52.4%	99.29%
Operating Profit	-$468.0M	-$232.3M	-$103.7M	-$89.58M	-$54.15M	-$35.53M
YoY Change	101.52%	124.03%	15.73%	65.42%	52.4%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017
Interest Expense	$0.00	$2.000K	$7.000K	$7.000K	$40.00K	$75.00K	$160.0K
YoY Change	-100.0%	-71.43%	0.0%	-82.5%	-46.67%	-53.13%
% of Operating Profit
Other Income/Expense, Net	$65.78M	$8.771M	$3.593M	$364.0K	$3.879M	$6.048M	$440.0K
YoY Change	649.91%	144.11%	887.09%	-90.62%	-35.86%	1274.55%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017
Pretax Income	-$402.3M	-$223.5M	-$100.1M	-$89.22M	-$50.27M	-$29.49M	-$17.24M
YoY Change	80.0%	123.31%	12.17%	77.48%	70.46%	71.06%
Income Tax
% Of Pretax Income
Net Earnings	-$402.3M	-$223.5M	-$100.1M	-$89.22M	-$50.27M	-$29.49M	-$17.24M
YoY Change	80.0%	123.31%	12.17%	77.46%	70.51%	71.03%
Net Earnings / Revenue
Basic Earnings Per Share	-$4.14	-$3.44	-$1.93	-$3.02
Diluted Earnings Per Share	-$4.14	-$3.44	-$1.927M	-$3.019M	-$1.039M	-$609.4K	-$356.3K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017
Cash & Short-Term Investments	$1.080B	$931.4M	$246.0M	$386.2M	$59.00M	$66.10M	$36.10M
YoY Change	15.98%	278.65%	-36.31%	554.58%	-10.74%	83.1%
Cash & Equivalents	$397.5M	$834.7M	$68.99M	$386.2M	$59.00M	$66.10M	$36.10M
Short-Term Investments	$682.8M	$96.72M	$177.0M
Other Short-Term Assets	$15.73M	$11.18M	$10.38M	$2.800M	$2.700M	$600.0K	$200.0K
YoY Change	40.68%	7.72%	270.64%	3.7%	350.0%	200.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$1.096B	$942.6M	$256.3M	$389.0M	$61.70M	$66.70M	$36.30M
YoY Change	16.27%	267.69%	-34.1%	530.47%	-7.5%	83.75%
Property, Plant & Equipment	$110.6M	$31.65M	$35.91M	$3.300M	$3.400M	$3.400M	$3.000M
YoY Change	249.54%	-11.87%	988.24%	-2.94%	0.0%	13.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$162.7M	$26.55M	$27.12M
YoY Change	512.73%	-2.09%
Other Assets	$38.67M	$5.426M	$4.960M	$600.0K	$600.0K	$700.0K	$300.0K
YoY Change	612.59%	9.4%	726.67%	0.0%	-14.29%	133.33%
Total Long-Term Assets	$312.0M	$63.62M	$67.99M	$3.800M	$4.000M	$4.100M	$3.300M
YoY Change	390.33%	-6.42%	1689.18%	-5.0%	-2.44%	24.24%
Total Assets	$1.408B	$1.006B	$324.3M	$392.8M	$65.70M	$70.80M	$39.60M
YoY Change
Accounts Payable	$14.59M	$9.795M	$6.758M	$29.80M	$3.400M	$2.800M	$1.800M
YoY Change	48.92%	44.94%	-77.32%	776.47%	21.43%	55.56%
Accrued Expenses	$130.8M	$30.73M	$21.96M	$17.10M	$7.700M	$3.900M	$2.500M
YoY Change	325.48%	39.95%	28.41%	122.08%	97.44%	56.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$145.3M	$40.53M	$28.72M	$46.90M	$11.10M	$6.700M	$4.300M
YoY Change	258.64%	41.12%	-38.77%	322.52%	65.67%	55.81%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$500.0K	$3.600M	$3.800M
YoY Change				-100.0%	-86.11%	-5.26%
Other Long-Term Liabilities	$22.11M	$12.04M	$11.60M	$100.0K	$300.0K	$400.0K	$700.0K
YoY Change	83.65%	3.77%	11503.0%	-66.67%	-25.0%	-42.86%
Total Long-Term Liabilities	$22.11M	$12.04M	$11.60M	$100.0K	$800.0K	$4.000M	$4.500M
YoY Change	83.65%	3.77%	11503.0%	-87.5%	-80.0%	-11.11%
Total Liabilities	$167.4M	$52.57M	$40.32M	$47.00M	$11.80M	$10.70M	$8.700M
YoY Change	218.56%	30.37%	-14.21%	298.31%	10.28%	22.99%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020
Basic Shares Outstanding	97.16M	64.88M	51.92M	29.55M
Diluted Shares Outstanding	97.16M	64.88M	51.92M	29.55M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $11.596 Billion

About Vaxcyte, Inc.

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. The company is headquartered in San Carlos, California and currently employs 254 full-time employees. The company went IPO on 2020-06-12. The company is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

Industry: Biological Products, (No Diagnostic Substances) Peers: AGIOS PHARMACEUTICALS, INC. Celldex Therapeutics, Inc. BridgeBio Pharma, Inc. Day One Biopharmaceuticals, Inc. IOVANCE BIOTHERAPEUTICS, INC. LIGAND PHARMACEUTICALS INC MYRIAD GENETICS INC NOVAVAX INC Xencor Inc